Revlimid
Showing 1 - 25 of 598
Multiple Myeloma Trial in Charlotte (Elotuzumab)
Active, not recruiting
- Multiple Myeloma
-
Charlotte, North CarolinaLevine Cancer Institute
Jan 24, 2023
Multiple Myeloma Trial (Dara-VRd intensification, Dara-R maintenance, AHCT intensification, Dara-R maintenance, AHCT
Not yet recruiting
- Multiple Myeloma
- Dara-VRd intensification, Dara-R maintenance
- +4 more
- (no location specified)
Dec 13, 2022
Multiple Myeloma Trial (RP followed by MPR)
Active, not recruiting
- Multiple Myeloma
- RP followed by MPR
- (no location specified)
Mar 24, 2022
Analyze Occurrence of Transformation From Myelodysplastic
Completed
- Myelodysplastic Syndromes
- Leukemia, Myeloid, Acute
-
Kobe, Hyogo, JapanShinko Hospital
Jun 13, 2022
Lymphoma, Non-Hodgkin Lymphoma, DLBCL Trial run by the National Cancer Institute (NCI) (Venetoclax, Ibrutinib, Prednisone)
Recruiting
- Lymphoma
- +3 more
- Venetoclax
- +4 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Aug 20, 2022
Chronic Lymphocytic Leukemia(CLL), Small Lymphocytic Lymphoma Trial in Hackensack (Revlimid, Azacitidine)
Terminated
- Chronic Lymphocytic Leukemia(CLL)
- Small Lymphocytic Lymphoma
- Revlimid
- Azacitidine
-
Hackensack, New JerseyHackensack University Medical Center
Jun 24, 2022
Multiple Myeloma Trial in New York (carfilzomib, Dexamethasone, Clarithromycin)
Active, not recruiting
- Multiple Myeloma
- carfilzomib
- +3 more
-
New York, New YorkWeill Cornell Medical College
Apr 10, 2022
Revlimid® Capsules General Drug Use-results Surveillance
Recruiting
- Lymphoma Nonhodgkin
-
Japan, JapanLocal Institution
Jun 22, 2022
Lymphoma, Non-Hodgkin Lymphoma, DLBCL Trial run by the NCI (obinutuzumab, prednisone, Revlimid)
Recruiting
- Lymphoma
- +3 more
- obinutuzumab
- +5 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jul 6, 2022
Myelodysplastic Syndrome Trial in New York (Revlimid (Lenalidomide))
Active, not recruiting
- Myelodysplastic Syndrome
- Revlimid (Lenalidomide)
-
New York, New YorkColumbia University Medical Center
Jan 12, 2022
Non-Hodgkin Lymphoma Trial in Cologne (Tafasitamab, Lenalidomide, Rituximab)
Not yet recruiting
- Non-Hodgkin Lymphoma
- Tafasitamab
- +3 more
-
Cologne, GermanyUniversity of Cologne
Oct 14, 2022
Multiple Myeloma Trial in Augusta (Lenalidomide, Vitamin D - Intensified, Vitamin D - Therapeutic)
Not yet recruiting
- Multiple Myeloma
- Lenalidomide
- +2 more
-
Augusta, GeorgiaGeorgia Cancer Center at Augusta University
Apr 26, 2023
Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Huntsville, Bethesda (Ublituximab,
Terminated
- Non-Hodgkins Lymphoma
- +6 more
-
Huntsville, Alabama
- +1 more
May 5, 2022
Primary Diffuse Large B-cell Lymphoma of the CNS (CNS), Aggressive B-cell Lymphoma With Secondary Involvement of the CNS Trial
Suspended
- Primary Diffuse Large B-cell Lymphoma of the Central Nervous System (CNS)
- Aggressive B-cell Lymphoma With Secondary Involvement of the CNS
- Obinutuzumab
- +5 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jul 6, 2022
Kyprolis® in Combination With Revlimid® and Dexamethasone or
Recruiting
- Multiple Myeloma in Relapse
-
Frankfurt, GermanyCentrum für Hämatologie und Onkologie Bethanien
Jun 2, 2022
Multiple Myeloma, Myeloma-Associated Amyloidosis Trial in Saint Louis (Selinexor, Lenalidomide, Dexamethasone)
Not yet recruiting
- Multiple Myeloma
- Myeloma-Associated Amyloidosis
- Selinexor
- +2 more
-
Saint Louis, MissouriWashington University School of Medicine
Apr 6, 2023
B-cell Non-Hodgkin's Lymphoma Trial (IMM0306, Lenalidomide capsule)
Not yet recruiting
- B-cell Non-Hodgkin's Lymphoma
- IMM0306
- Lenalidomide capsule
- (no location specified)
Mar 6, 2023
Multiple Myeloma, Primary Plasma Cell Leukemia, Extramedullary Multiple Myeloma Trial in Wuhan (Daratumumab, Carfilzomib,
Recruiting
- Multiple Myeloma
- +2 more
- Daratumumab
- +10 more
-
Wuhan, Hubei, ChinaInstitute of Hematology, Union Hospital, Tongji Medical College,
Nov 18, 2023
Chronic Lymphocytic Leukemia, CLL Trial in La Jolla (Revlimid, Rituximab)
Active, not recruiting
- Chronic Lymphocytic Leukemia
- CLL
- Revlimid
- Rituximab
-
La Jolla, CaliforniaUniversity of California, San Diego
Sep 2, 2021
Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma (MZL) Trial in Chiang Mai (Odronextamab, Lenalidomide,
Recruiting
- Relapsed/Refractory Follicular Lymphoma
- Marginal Zone Lymphoma (MZL)
- Odronextamab
- +2 more
-
Chiang Mai, ThailandChiang Mai University
Nov 20, 2023
High-risk Smoldering Multiple Myeloma, Smoldering Multiple Myeloma, Multiple Myeloma Trial in Boston (Teclistamab, Lenalidomide,
Recruiting
- High-risk Smoldering Multiple Myeloma
- +2 more
- Teclistamab
- +2 more
-
Boston, MassachusettsDana Farber Cancer Institute
Aug 11, 2022
Diffuse Large B Cell Lymphoma Trial (Epcoritamab, Lenalidomide)
Not yet recruiting
- Diffuse Large B Cell Lymphoma
- Epcoritamab
- Lenalidomide
- (no location specified)
Jan 20, 2023